Additionally, metabolic profiling was conducted to analyze changes in metabolic pathways.<h4>Results</h4>TMQ0153 treatment significantly reduced OPA1 and mitofusin (MFN)2 protein levels and disrupted the mitochondrial morphology and function in AML cells. The gene discussed is MFN2; the disease is acute myeloid leukemia.